Pediatric Neurology News

Children born to women with epilepsy who received antiepileptic drugs during pregnancy displayed similar neurodevelopmental outcomes as children born to healthy women, according to findings from a prospective study.

Preliminary research suggested half of children at a London hospital who developed a multisystem inflammatory syndrome associated with COVID-19 experienced neurological symptoms, such as headache, encephalopathy and hallucinations.

A review of research on cerebral palsy from the past decade resulted in varying evidence for “several key principles” that encourage early motor development and leverage “greater potential and brain plasticity” during this period.

The FDA ordered additional studies for Lamictal following a review of current research by the agency that demonstrated the potential for an increased risk for arrhythmias in patients with heart disease who are taking Lamictal.

Children and teens who had a concussion and subsequently reported occipital headaches and photophobia took more time to return to their pre-concussion state than those who did not report these symptoms, data show.

Some children with traumatic brain injury experienced a decline in cognitive function following a recovery plateau, indicating the need for long-term reassessment of these patients, according to research published in JAMA Network Open.

Researchers have identified “critical pathways” and “novel proteins” that may be considered potential drug targets for patients with epilepsy, according to findings published in bioRxiv.

Emflaza, a corticosteroid, improved or stabilized disease progression in most patients with Duchenne muscular dystrophy or Becker muscular dystrophy who switched from prednisone, according to a press release.

Children and young adults who experience post-traumatic headache with migraine phenotype may be at increased risk for more significant injury or deleterious pathophysiology after concussion.

Evrysdi, a survival motor neuron 2-directed RNA splicing modifier, both sustained and improved motor function at 24 months in children and adults with type 2 or type 3 spinal muscular atrophy, according to results from the SUNFISH trial.